TY - T1的全球评估肺功能行动(GLI)参考方程扩散能力与呼吸的负担在瑞典心肺BioImage研究(SCAPIS) JF -欧洲呼吸杂志乔-和J欧元做10.1183/13993003.01995 -2019 SP - 1901995 AU Malinovschi安德烈•周盟——室内盟——烤,Bjorn盟——Bergstrom Goran盟,显得过于安德斯AU -布里斯曼,乔纳斯盟——Caidahl Kenneth AU - Engstrom贡纳AU -埃里克森,玛丽亚·J . AU - Frølich Andreas AU -詹森,Christer盟——简颂谢尔盟——Vikgren詹妮非盟-林德伯格,安妮AU -林德,罗伯特•AU - Mannila玛丽亚AU -佩尔森,汉斯Lennart AU - Skold教授,c·马格纳斯盟——Toren谢尔盟——Ostgren卡尔约翰盟——Wollmer / AU - Engvall, Jan大肠Y1 - 2020/01/01 UR - //www.qdcxjkg.com/content/early/2020/04/01/13993003.01995 - 2019. -抽象N2 -全球肺功能行动(GLI)最近出版的国际参考值扩散能力的肺一氧化碳(DLCO)。正常的下限(LLN),即第五百分位,通常定义DLCO受损。我们研究如果GLI LLN DLCO不同于LLN瑞典人口的健康,从不吸烟个人和任何此类差异如何影响识别的主题与呼吸的负担。肺量测定法、DLCO、胸部高分辨率计算机断层扫描和问卷获得第一个15 040名参与者,年龄在50 - 64年,瑞典的心肺bioImage研究(SCAPIS)。GLI参考价值和lambda-mu-sigma方法被用来定义LLN在无症状的不吸烟者呼吸道疾病(n = 4903 2329名女性)。SCAPIS值和LLN DLCO GLI中等以上,LLN(术中,0.05)。的患病率DLCO & lt; GLI LLN (& lt; SCAPIS LLN)是3.9%,而DLCO & lt的患病率;SCAPIS LLN,但祝辞GLI LLN是5.7%。受试者DLCO祝辞GLI LLN,但& lt; SCAPIS LLN (n = 860)有更多的肺气肿(14.3%比4.5%,术中;0.001),慢性气流限制(8.5%比3.9%,术中;0.001)和慢性支气管炎(8.3%比4.4%,术中;0.01)比正常受试者DLCO(祝辞LLN GLI和祝辞LLN SCAPIS) 13 (n = 600)。没有发现差异对被诊断出的哮喘。GLI LLN DLCO低于估计LLN在瑞典健康,从不吸烟的中年人。个人DLCO GLI LLN以上,但低于SCAPIS LLN,必须更大程度上增加呼吸的负担。这表明临床意义的选择适当的LLN种群进行了研究。FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: Dr. Malinovschi has nothing to disclose.Conflict of interest: Dr. Zhou has nothing to disclose.Conflict of interest: Dr. Bake has nothing to disclose.Conflict of interest: Dr. Bergström has nothing to disclose.Conflict of interest: Dr. Blomberg has nothing to disclose.Conflict of interest: Dr. Brisman has nothing to disclose.Conflict of interest: Dr. Caidahl has nothing to disclose.Conflict of interest: Dr. Engström has nothing to disclose.Conflict of interest: Dr. Eriksson has nothing to disclose.Conflict of interest: Dr. Frølich has nothing to disclose.Conflict of interest: Dr. Janson has nothing to disclose.Conflict of interest: Dr. Jansson has nothing to disclose.Conflict of interest: Payment 1-2 lectures annually from Boerhinger -Ingelheim concerning fibrosisConflict of interest: Dr. Lindberg reports personal fees from Boehringer-Ingelheim, personal fees from AstraZeneca, personal fees from Novartis, personal fees from Active Care, outside the submitted work.Conflict of interest: Dr. Linder has nothing to disclose.Conflict of interest: Dr. Mannila has nothing to disclose.Conflict of interest: Dr. Persson has nothing to disclose.Conflict of interest: Dr. Sköld has nothing to disclose.Conflict of interest: Dr. Torén has nothing to disclose.Conflict of interest: Dr. Ostgren has nothing to disclose.Conflict of interest: Dr. Wollmer reports grants from Swedish Heart and Lung Foundation, during the conduct of the study; personal fees from Chiesi Pharma, personal fees from AstraZeneca, outside the submitted work; In addition, Dr. Wollmer has a patent Device and method for pulmonary function measurement issued.Conflict of interest: Dr. Engvall has nothing to disclose. ER -